MERIT MEDICAL SYSTEMS INC
For the period ended May 13, 2026. Filed Mar 31, 2026.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
May 13, 2026 · Filed Mar 31, 2026
MMSI$87.23-2.7%Stored close · as of Nov 6, 2026
Contents
Directors Whose Terms of Office Continue
In its regular discussions regarding Board composition, our Governance Committee works with the Board to determine the appropriate mix of professional experience, areas of expertise, educational background and other qualifications that are particularly desirable for our directors to possess in light of our current and future business strategies.
The Board believes that its current members have the right combination of experience and qualifications to continue to lead the Company to success. Information regarding the specific experience, qualifications, attributes and skills that led the Board and the Governance Committee to conclude that each continuing director should serve on the Board are set forth below:
| LAURA S. KAISERIndependent Director Age: 65Director Since: May 2022Committees: Governance, CompensationOther Public Boards: NoneEducation: B.S. (health sciences management), University of Missouri; M.B.A., Saint Louis University; Masters of Health Administration, Saint Louis UniversityTerm Expires: 2028 | | SILVIA M. PEREZIndependent DirectorAge: 59Director Since: May 2024Other Public Boards: NoneCommittees: Audit, GovernanceEducation: Pharmaceutical Chemist, University of the Republic (Uruguay); Industrial Pharmacist, Federal University of Parana (Brazil)Term Expires: 2027 | ||
|---|---|---|---|---|
| | | | | |
| Career Highlights●President and Chief Executive Officer of SSM Health, an integrated multi-state health system with more than 40,000 employees and 35 hospitals, medical group, health plan and pharmacy benefit management company, 2017 to present●Former Chair of Catholic Health Association of the United States, representing more than 600 hospitals and 1,600 long-term care and other health facilities in all 50 states, 2018 to 2024●Board Director, American Hospital Association, 2024 to present●Served on the Board of Directors for Nuance Communications, a multinational computer technology company acquired by Microsoft Corp., 2017 to 2022●Previously served as the Chief Operating Officer of Intermountain Health, an integrated multi-state health system with 24 hospitals, 2012 to 2017●Named one of the “100 Most Influential People in Healthcare” by Modern Healthcare for the past seven yearsQualifications of Particular Relevance to MeritMs. Kaiser is a seasoned executive with more than 35 years of experience in the healthcare industry. The Board believes her senior leadership experience in healthcare and her consistent delivery of operational results, strategic expertise, market growth and innovative partnerships with organizations such as Costco, Medica, Civica and Siemens, enable her to provide valuable industry and organizational perspective to the Board and the Company’s management team. The Board also believes Ms. Kaiser’s deep industry experience allows her to provide insight regarding merger and acquisition opportunities and transactions, regulatory initiatives and compliance, and governmental policies. | | Career Highlights●President of Commercial Branding and Transportation, a $2.6 billion revenue division of 3M Company, a multinational NYSE-listed company operating in the fields of industry, consumer goods and worker safety, 2023 to present●President of Commercial Solutions Division of 3M Company, an approximate $1.8 billion revenue division, 2020 to 2023 ●Interim President of Acelity acquisition, overseeing the integration of Acelity into 3M Company, which was the largest acquisition in the history of 3M Company, 2019 to 2020●Various leadership roles within the healthcare business of 3M Company, both domestic and international, 1994 to 2019 ●Obtained Six Sigma Black Belt and Master Black Belt CertificationsQualifications of Particular Relevance to MeritMs. Perez brings a 25-plus year career in the healthcare industry with a broad background spanning clinical, regulatory, operations, marketing, and business leadership. The Board believes her broad experience and proven track record of leadership success enable her to provide valuable industry and organizational perspective to the Board and the Company’s management team. The Board also believes Ms. Perez’s first-hand experience with post-acquisition business integration aids the Company in its strategic merger and acquisition endeavors. | ||
| | | | | |
| : 74 May 2017 Finance (Chair), Audit TransMedics Group, Inc. B.A. (biology focus), Carleton College; M.S. (cell biology), University of Minnesota; M.B.A., University of St. Thomas 2025 | : 64 May 2022 Governance, Compensation None B.S. (health sciences management), University of Missouri; M.B.A., Saint Louis University; Masters of Health Administration, Saint Louis University 2025 | |||
|---|---|---|---|---|
| THOMAS J. GUNDERSONIndependent DirectorAge: 75Director Since: May 2017Committees: Finance (Chair), CompensationOther Public Boards: TransMedics Group, Inc.Education: B.A. (biology focus), Carleton College; M.S. (cell biology), University of Minnesota; M.B.A., University of St. ThomasTerm Expires: 2028 | F. ANN MILLNER, Ed.D.Chair of the Board of DirectorsAge: 74Director Since: July 2015Committees: Governance, CompensationOther Public Boards: NoneEducation: B.S. (education), University of Tennessee; M.S. (allied health education and management), Southwest Texas State University; Ed.D (education administration), Brigham Young University; Completed medical technology program, Vanderbilt UniversityTerm Expires: 2028 | |||
| | | | | |
| Career Highlights●Member of the Board of Directors of TransMedics Group, Inc., a medical technology company focused on developing organ transplant therapy for end-stage organ failure patients, 2019 to present●Chair of the Minneapolis Heart Institute Foundation, (Director from 2011 to present, Chair from 2015 to 2020 and 2024 to present)●Executive in Residence at the University of Minnesota’s Medical Industry Leadership Institute, 2016 to present●Member of American Heart Association Science and Technology Accelerator Committee, 2015 to 2017●Managing Director and senior research analyst at Piper Jaffray (focus on medical technology companies), 1992 to 2016●Project Director at American Medical Systems (private medical device company acquired by Pfizer in 1983), 1979 to 1992●Recognized by several industry publications, including the Wall Street Journal, Institutional Investor, First Call, Thomson Reuters, and Medical Device and Diagnostic Industry (e.g., in 1996 and 2000, he was named an All-Star Analyst for medical stocks by the Wall Street Journal and in 2014, Thomson-Reuters named him “Top Stock Picker” in the medical technology sector)Qualifications of Particular Relevance to MeritMr. Gunderson provides the Board with more than 30 years of substantive experience in the medical device industry, with a seasoned perspective on the challenges, trends and opportunities of publicly-traded medical device manufacturers, as well as a keen understanding of the Company’s competitive position within its industry. Mr. Gunderson also contributes a strong background in financial and economic analysis and valuable insights regarding business development and acquisition opportunities. Mr. Gunderson’s financial background and industry experience have been beneficial in his service as the Chair of the Finance Committee. | | Career Highlights●Regents Professor and Professor of Health Administrative Services at Weber State University, 2013 to June 2025●Member of the Utah State Senate (member of multiple committees and subcommittees), 2015 to present ●Executive Committee of National Conference of State Legislatures, 2023 to present●Member of Board of Trustees of Intermountain Health (integrated multi-state health system), 2005 to present ●President of Weber State University, 2002 to 2012 (first female president of a Utah state university)●Vice President of University Relations at Weber State University, 1993 to 2002●Associate Dean of Continuing Education and Assistant Vice President of Community Partnerships at Weber State University, 1985 to 1993Qualifications of Particular Relevance to MeritThe Board believes Dr. Millner's qualifications to serve as a director of the Company include her executive leadership skills and her experience in the areas of organizational administration, operations and financial management, and business strategy. Those skills and experience have been particularly valuable to the Company in the course of Dr. Millner’s service Chair of the Board and her prior service as Lead Independent Director and Chair of the Governance Committee. During her service, Dr. Millner has played a significant role in the development of our corporate governance practices and executive leadership transition. | ||
10| Understand. Innovate. Deliver. TM
| 61 May 2022 Audit, Finance NoneB.S. (accounting), Georgetown University 2025 | 73 July 2015 Governance, Compensation NoneB.S. (education), University of Tennessee; M.S. (allied health education and management), Southwest Texas State University; Ed.D (education administration), Brigham Young University; Completed medical technology program, Vanderbilt University 2025 | |||
|---|---|---|---|---|
| MICHAEL R. MCDONNELLIndependent DirectorAge: 62Director Since: May 2022Committees: Audit (Chair), FinanceOther Public Boards: Baxter International, Inc.Education: B.S. (accounting), Georgetown UniversityTerm Expires: 2028 | REAR ADMIRAL (RET.) STEPHEN C. EVANSIndependent DirectorAge: 61Director Since: June 2021Committees: Audit, CompensationOther Public Boards: Alarm.com Holdings, Inc.Education: M.A., U.S. Naval War College (National Security Affairs), B.A., The CitadelTerm Expires: 2027 | |||
| | | | | |
| Career Highlights●Director of Baxter International, February 2026 to present●Advisor to Goldman Sachs Asset Management and Leader of Finance Center of Excellence for Private Equity Buyout Funds, 2025 to present●Chief Financial Officer of Biogen Inc, a multinational Nasdaq-listed company engaged in discovering, developing, and delivering therapies for people living with serious and complex diseases, 2020 to 2025●Executive Vice President and Chief Financial Officer of IQVIA Holdings Inc., a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry, 2015 to 2020●Executive Vice President and Chief Financial Officer of Intelsat, a global provider of satellite services, 2008-2015●Chief Operating Officer (2006-2008) and Chief Financial Officer (2004-2008) of MCG Capital Corporation, a publicly-held commercial finance company, 2004 to 2008●Chief Financial Officer of EchoStar Communications Corporation (dba Dish Network), a satellite television provider, 2000 to 2004●Partner of PricewaterhouseCoopers, LLP, 1996 to 2000, other positions, PricewaterhouseCoopers, LLP, 1986-1996●Director of Catalyst Health Solutions, Inc., a publicly-held pharmacy benefits management company, 2005 to 2012●Finance Committee Member, Atlantic Health System, owner and operator of over 400 care sites including six hospitals in New Jersey, 2021 to present●Certified public accountant Qualifications of Particular Relevance to MeritMr. McDonnell is a financial executive with more than 35 years of experience providing financial and accounting advice and oversight to life science and technology companies and over 24 years serving as a public company CFO. The Board believes Mr. McDonnell’s depth of understanding of financial management, accounting principles and practices, capital markets and financing transactions strengthen the Board’s oversight of the Company’s finance and accounting policies, procedures and practices. The Board also believes Mr. McDonnell’s industry experience enables him to contribute to the Board’s evaluation and oversight of merger and acquisition and capital funding transactions, as well as the Company’s investor relations and shareholder outreach efforts. The Board also recognizes the valuable perspective and significant service Mr. McDonnell provides to the Company as Chair of the Audit Committee. | | Career Highlights●Served in the United States Navy, most recently as Special Advisor to the Commander, Naval Operations, before retiring in 2020. During more than 20 years of service in the United States Navy, Admiral Evans held a variety of leadership positions, including Senior Advisor, Deputy U.S. Military, NATO Military Committee; Commander, George H. W. Bush Carrier Strike Group; and Commander, Naval Service Training Command●Served on diplomatic missions in over 64 countries, delivering results in international diplomacy and military relations to establish enduring, productive global partnerships●Commanded U.S. naval forces in six operational theaters●Served in a senior strategic advisory role to the 75th Secretary of the Navy●Represented the U.S. in deliberations and actions of NATO, providing counsel to Heads of State in Europe and around the worldQualifications of Particular Relevance to MeritAdmiral Evans possesses extensive experience in handling complex, international relationships. His prior leadership experiences, particularly within the last two decades, involved extensive cybersecurity oversight, and he has broad experience in anticipating and identifying cyber risks and digital vulnerabilities. Admiral Evans’ cybersecurity experience is of particular importance to the Company as we seek to secure our information technology and build secure and effective information systems and to assess and mitigate potential cybersecurity risk. Admiral Evans has extensive insight on geo-political matters, and the Board believes that, together with his experience in handling global partnerships, he provides valuable counsel to the Company as it seeks to expand its operations and sales efforts across the globe. | ||
| : 57 None Pharmaceutical Chemist ], University of the Republic (Uruguay); Industrial Pharmacist, Federal University of Parana (Brazil) New Nominee | ||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.